Überwachung der Bauchspeicheldrüsengesundheit nach Diabetesdiagnose (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: SAFE-D Trial Manager
- Telefonnummer: +442381205154
- E-Mail: safed@soton.ac.uk
Studienorte
-
-
-
Ashton-under-Lyne, Vereinigtes Königreich, OL6 6HD
- Aktiv, nicht rekrutierend
- Ashton Medical Group
-
Birmingham, Vereinigtes Königreich, B14 4DU
- Rekrutierung
- Yardley Wood Health Centre
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Bournemouth, Vereinigtes Königreich, BH7 7DW
- Aktiv, nicht rekrutierend
- Bournemouth Research Hub
-
Bromborough, Vereinigtes Königreich, CH62 6EE
- Rekrutierung
- Eastham Group Practice
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
London, Vereinigtes Königreich, NW10 2PT
- Rekrutierung
- Willesden Medical Centre
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
London, Vereinigtes Königreich, SW1P 2PF
- Rekrutierung
- South Westminster Centre
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
London, Vereinigtes Königreich, W7 1DR
- Rekrutierung
- The Cuckoo Lane Practice
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Manchester, Vereinigtes Königreich, M14 6WP
- Aktiv, nicht rekrutierend
- Bodey Medical Centre
-
Manchester, Vereinigtes Königreich, M23 1JX
- Aktiv, nicht rekrutierend
- Bowland Medical Practice
-
Manchester, Vereinigtes Königreich, M23 2SY
- Aktiv, nicht rekrutierend
- The Maples Medical Centre
-
Nottingham, Vereinigtes Königreich, NG17 4JL
- Rekrutierung
- King's Mill Hospital (Sherwood Forest) Research Van
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Portsmouth, Vereinigtes Königreich, PO1 3HN
- Aktiv, nicht rekrutierend
- Portsmouth Research Hub
-
Rossendale, Vereinigtes Königreich, BB4 5SL
- Rekrutierung
- Hazelvalley Family Practice
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Ruislip, Vereinigtes Königreich, HA4 8NX
- Rekrutierung
- Pembroke Centre (Hillingdon)
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Southampton, Vereinigtes Königreich, SO30 3JB
- Rekrutierung
- Moorgreen Hospital
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Southampton, Vereinigtes Königreich, SO15 33UA
- Aktiv, nicht rekrutierend
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Vereinigtes Königreich, ST14 8JG
- Rekrutierung
- Balance Street Health Centre
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Uxbridge, Vereinigtes Königreich, UB8 1UW
- Rekrutierung
- Civic Centre
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Walsall, Vereinigtes Königreich, WS6 6EW
- Rekrutierung
- Quinton Practice
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Weymouth, Vereinigtes Königreich, DT4 0QE
- Aktiv, nicht rekrutierend
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Vereinigtes Königreich, CW11 1EQ
- Aktiv, nicht rekrutierend
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Vereinigtes Königreich, ME16 9QQ
- Rekrutierung
- Maidstone and Tunbridge Wells NHS Trust
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Vereinigtes Königreich, LE3 3LW
- Rekrutierung
- Forest Medical Group
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Vereinigtes Königreich, LE8 0LG
- Rekrutierung
- South Leicestershire Medical Group
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Vereinigtes Königreich, DE14 3RH
- Rekrutierung
- Peel Croft Surgery
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Vereinigtes Königreich, DY6 8DN
- Rekrutierung
- Kingswinford Medical Practice
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Leek, Staffordshire, Vereinigtes Königreich, ST13 6QR
- Rekrutierung
- Park Medical Centre
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Vereinigtes Königreich, CV37 6HJ
- Rekrutierung
- Trinity Court Surgery
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Vereinigtes Königreich, RH3 7NJ
- Rekrutierung
- Brockwood Medical Practice
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Epsom, Surrey, Vereinigtes Königreich, KT17 4BL
- Rekrutierung
- Integrated Care Partnership/ The Old Cottage Hospital
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
Warlingham, Surrey, Vereinigtes Königreich, CR6 9NW
- Rekrutierung
- Warlingham Green Medical Practice
-
Kontakt:
- Anson-Wisniewska
- Telefonnummer: 02380215154
- E-Mail: safed@soton.ac.uk
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sensitivity of the Avantect test
Zeitfenster: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Zeitfenster: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Stage shift
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Zeitfenster: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time-to-event outcomes
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Zeitfenster: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Neubildungen nach Standort
- Neubildungen
- Stoffwechselerkrankungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Störungen des Glukosestoffwechsels
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Ernährungs- und Stoffwechselerkrankungen
- Diabetes mellitus, Typ 2
- Neoplasmen der Bauchspeicheldrüse
- Diabetes Mellitus
- Bauchspeicheldrüsenkrebs, Erwachsener
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- RHMGSU0292
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .